<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217409</url>
  </required_header>
  <id_info>
    <org_study_id>YMC022</org_study_id>
    <nct_id>NCT03217409</nct_id>
  </id_info>
  <brief_title>A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia</brief_title>
  <official_title>A Multicenter Clinical Trial to Compare the Efficacy and Safety Between Rosuvastatin/Ezetimibe Combination and Monotherapy of Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linical Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Compare Rosuvastatin/Ezetimibe Combination and Monotherapy in Patients with
      Diabetes Mellitus and Hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is conducted to compare the efficacy and safety between Rosuvastatin/Ezetimibe
      combination and Rosuvastatin monotherapy in patients with Diabetes Mellitus and
      Hypercholesterolemia for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C) (%)</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>The rate of change(%) of LDL-C at Week 8 compared to the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C) (100mg/dL)</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>The ratio of patients who reached the treatment target (100mg/dL) of LDL-C at Week 8 compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß)</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>Variation of HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) at Week 8 compared to the baseline resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) change form the baseline at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C)</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>Variation of LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) at Week 8 compared to the baseline Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) change form the base line at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thiobarbituric acid reactive substances(TBARs)</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>Absolute value change of Thiobarbituric acid reactive substances(TBARs) at Week 8 compared to baseline to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast Growth Factor 21</measure>
    <time_frame>baseline, Week 8</time_frame>
    <description>Absolute value change of Fibroblast Growth Factor 21 at Week 8 compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Diabetes Mellitus and Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin+Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Ezetimibe</intervention_name>
    <description>Rosuvastatin 5mg+Ezetimibe 10mg</description>
    <arm_group_label>Rosuvastatin+Ezetimibe</arm_group_label>
    <other_name>Rosuvamibe ® 10/5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 5Mg Tablet</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Monorova ® 5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 19 or ≤ 75 years of age

          -  Subjects undergoing treatment for type 2 diabetes

          -  Subjects undergoing treatment of statin for hypercholesterolemia

          -  Fasting LDL-C ≤ 250mg/dL at the screening visit

          -  Fasting LDL-C ≥70mg/dL or ≤ 160mg/dL at the randomization visit

          -  Fasting TG＜500mg/dL

        Exclusion Criteria:

          -  Subjects with hypersensitivity reaction to Statin and Ezetimibe

          -  Subjects with severe kidney disease

          -  Subjects with HIV positive result at the screening

          -  Pregnant or breast-feeding subjects

          -  Subjects with taking any medication affecting level of LDL (Fenofibrate, Omega 3 fatty
             aicd etc.)

          -  Insulin-treated Subjects

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hojin Lee</last_name>
    <phone>82 2 828 0548</phone>
    <email>hjlee@yuhan.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gahee Choi</last_name>
    <phone>82 2 70 4504 6700</phone>
    <email>Gahee.Choi@linical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Gumi</name>
      <address>
        <city>Gumi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

